Editas Medicine [EDIT] vs Vertex [VRTX] Detailed Stock Comparison
Editas Medicine
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Editas Medicine wins in 5 metrics, Vertex wins in 12 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Editas Medicine | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -0.86 | 27.77 | Editas Medicine |
| Price-to-Book Ratio | 11.68 | 5.83 | Vertex |
| Debt-to-Equity Ratio | 110.14 | 8.89 | Vertex |
| PEG Ratio | 0.04 | -0.22 | Vertex |
| EV/EBITDA | -0.48 | 19.87 | Editas Medicine |
| Profit Margin (TTM) | 0.00% | 31.86% | Vertex |
| Operating Margin (TTM) | -711.63% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | -188.58% | 22.77% | Vertex |
| Return on Assets (TTM) | -33.76% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-219.11M | $-978.00M | Editas Medicine |
| 1-Year Return | -31.28% | -21.15% | Vertex |
| Price-to-Sales Ratio (TTM) | 5.94 | 8.78 | Editas Medicine |
| Enterprise Value | $73.73M | $95.40B | Vertex |
| EV/Revenue Ratio | 1.90 | 8.36 | Editas Medicine |
| Gross Profit Margin (TTM) | N/A | 86.25% | N/A |
| Revenue per Share (TTM) | $0 | $44 | Vertex |
| Earnings per Share (Diluted) | $-2.84 | $14.08 | Vertex |
| Beta (Stock Volatility) | 2.20 | 0.44 | Vertex |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Editas Medicine vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Editas Medicine | -3.02% | -8.21% | -0.77% | 40.44% | 33.85% | 96.18% |
| Vertex | -0.26% | -1.04% | -16.52% | -12.54% | -18.50% | -3.63% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Editas Medicine | -31.28% | -82.67% | -91.57% | -85.40% | -85.40% | -85.40% |
| Vertex | -21.15% | 39.13% | 46.72% | 207.91% | 984.36% | 2,084.47% |
Performance & Financial Health Analysis: Editas Medicine vs Vertex
| Metric | EDIT | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $146.11M | $124.11B |
| Market Cap Category | Micro cap | Large cap |
| 10 Day Avg. Volume | 1,079,030 | 1,583,730 |
| 90 Day Avg. Volume | 2,023,140 | 2,118,280 |
| Last Close | $2.57 | $391.02 |
| 52 Week Range | $0.91 - $4.12 | $362.50 - $519.88 |
| % from 52W High | -37.62% | -24.79% |
| All-Time High | $99.95 (Jan 04, 2021) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -97.43% | -24.79% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 5.98% | 0.12% |
| Quarterly Earnings Growth | 5.97% | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.32% |
| Operating Margin (TTM) | -7.12% | 0.39% |
| Return on Equity (TTM) | -1.89% | 0.23% |
| Debt to Equity (MRQ) | 110.14 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.22 | $67.02 |
| Cash per Share (MRQ) | $1.99 | $24.90 |
| Operating Cash Flow (TTM) | $-201,360,992 | $3.85B |
| Levered Free Cash Flow (TTM) | $-78,909,872 | $2.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Editas Medicine vs Vertex
| Metric | EDIT | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -0.86 | 27.77 |
| Forward P/E | -1.09 | 20.83 |
| PEG Ratio | 0.04 | -0.22 |
| Price to Sales (TTM) | 5.94 | 8.78 |
| Price to Book (MRQ) | 11.68 | 5.83 |
| Market Capitalization | ||
| Market Capitalization | $146.11M | $124.11B |
| Enterprise Value | $73.73M | $95.40B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.90 | 8.36 |
| Enterprise to EBITDA | -0.48 | 19.87 |
| Risk & Other Metrics | ||
| Beta | 2.20 | 0.44 |
| Book Value per Share (MRQ) | $0.22 | $67.02 |
Financial Statements Comparison: Editas Medicine vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | EDIT | VRTX |
|---|---|---|
| Revenue/Sales | $4.66M | $2.96B |
| Cost of Goods Sold | N/A | $407.50M |
| Gross Profit | N/A | $2.56B |
| Research & Development | $26.59M | $978.40M |
| Operating Income (EBIT) | $-35.31M | $1.15B |
| EBITDA | $-31.10M | $1.34B |
| Pre-Tax Income | $-76.09M | $1.28B |
| Income Tax | N/A | $250.10M |
| Net Income (Profit) | $-76.09M | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | EDIT | VRTX |
|---|---|---|
| Cash & Equivalents | $138.69M | $4.67B |
| Total Current Assets | $224.84M | $10.01B |
| Total Current Liabilities | $73.11M | $3.78B |
| Long-Term Debt | $17.97M | $1.65B |
| Total Shareholders Equity | $62.42M | $16.50B |
| Retained Earnings | $-1.54B | $10.25B |
| Property, Plant & Equipment | $47.50M | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | EDIT | VRTX |
|---|---|---|
| Operating Cash Flow | $-52.70M | $404.90M |
| Capital Expenditures | $-114,000 | $-40.70M |
| Free Cash Flow | $-47.91M | $778.20M |
| Debt Repayment | N/A | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | EDIT | VRTX |
|---|---|---|
| Shares Short | 8.20M | 3.70M |
| Short Ratio | 3.37 | 1.72 |
| Short % of Float | 0.09% | 0.02% |
| Average Daily Volume (10 Day) | 1,079,030 | 1,583,730 |
| Average Daily Volume (90 Day) | 2,023,140 | 2,118,280 |
| Shares Outstanding | 82.73M | 256.94M |
| Float Shares | 89.58M | 255.58M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.49% | 0.98% |
Dividend Analysis & Yield Comparison: Editas Medicine vs Vertex
| Metric | EDIT | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |